TC
LGND icon

Trilogy Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Trilogy Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-37
Closed -$6K – 381
2018
Q3 		$6K Buy
+37
New +$5.58K ﹤0.01% 379

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Trilogy Capital's LGND Position: Q4 2018 in Review

Trilogy Capital sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 37 shares — an estimated $6K sold.

Trilogy Capital first reported a position in LGND in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

  • Trilogy Capital reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Trilogy Capital sold 37 Ligand Pharmaceuticals shares in Q4 2018, an estimated $6K.
  • Trilogy Capital first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Trilogy Capital's Ligand Pharmaceuticals position peaked at $6K in Q3 2018.
  • 362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.